WBMT Global Survey. Helen Baldomero Cape Town November Worldwide Network for Blood and Marrow Transplantation

Transcription

1 WBMT Global Survey Helen Baldomero Cape Town November 214 NGO in official relations with World Health Organization

2 Leukemias LPD Solid tumors Non - Malignant disorders NGO in official relations with World Health Organization WBMT Survey Sheet A simple questionnaire to report the annual overview of transplant activity by: Country/Hospital: National/Regional group:. No. Teams reporting:. No. Teams not reporting:.... (known to transplant but do not report) Family Unrelated Unrelate Family HLA - id sibling non - id* twin d Allo auto Total total total Indication BM PBSC Cord BM PBSC Cord BM PBSC BM PBSC Cord BM PBSC Cord Total Leukemia Total AML Total ALL AML ALL 1st CR non 1st CR 1st CR NUMBER OF PATIENTS RECEIVING FIRST TRANSPLANTS ONLY IN 211 Allogeneic WBMT SURVEY ON TRANSPLANT ACTIVITY 211 Autologous Total Team/country diagnosis donor type stem cell source non 1st CR Total CML CML 1st cp not 1st cp Other Leukemia Total MDS/MPS (incl. combined MDS/MPS) MDS incl. Sec AL MPS CLL incl. PLL Total LPD Total Plasma Cell Disorder PCD - Myeloma 1 survey per year Data is either provided by a regional transplant society, National Registry or at the team level Provides us with an rapid overview of annual data It is not part of an outcome registry PCD - other Total Lymphoma HD NHL Other LPD Total Solid tumors Neuroblastoma Germ cell tumor Breast Cancer Ewing Other solid tumor Total Non-malignant dis. Total Bone Marrow Failure BMF - SAA BMF - other Hemoglobinopathy Primary Immune Deficiency Inherited Dis of Metabolism Auto Immune Disease Other Non Malignant Disease Other TOTAL (patients) EBMT CIC No. / CIBMTR Code / APBMT No./ LABMT No. (if member):..

3 WBMT Global Survey 212 Transplant Rates per 1 million population Total HSCT in 212 or no report > 5 Hong Kong Singapore Preliminary data NGO in official relations with World Health Organization HB: Nov 214

4 WBMT Global Survey 212 Allogeneic Hong Kong Singapore Autologous Hong Kong Singapore NGO in official relations with World Health Organization HB: Nov 214

5 WBMT Global Survey 212 Regional variation: allogeneic HSCT 1% 9% 8% 7% 6% 5% 4% NM allo LPD allo Leuk allo 3% 2% 1% % SEAR/WPR EMR/AFR EUR AMR/PAH Preliminary data NGO in official relations with World Health Organization HB: Nov 214

6 Global Activity Survey: Allogeneic Autologous Acute Leuk/other leuk/mds/mps % Chronic Leuk Lymphoproliferative disorders % Solid Tumors Overall number of transplants : Non Malignant disorders % Allogeneic HSCT: BMF % Others Family: Total % Leukemias % Autologous HSCT: Unrelated: PCD % Lymphomas % Solid Tumors % Non Malignant disorders % Others % Total % Total % NGO in official relations with World Health Organization 212 preliminary data

7 HSCT HSCT Trend by region: Allogeneic HSCT: % increase since 26 Autologous HSCT: % increase since 26 EUR 45% EUR 25% AMR/PAH 32% AMR/PAH 43% SEAR/WPR 85% SEAR/WPR 44% EMR/AFR 47 % EMR/AFR 15% Preliminary data NGO in official relations with World Health Organization HB: Nov 214

8 HSCT HSCT HSCT HSCT Trend over 7 years: AML and BMF AML Family AML Unrelated Europe Asia Americas East Med Europe Americas Asia BMF Family BMF Unrelated Europe Asia Americas East Med Europe Asia Americas NGO in official relations with World Health Organization Preliminary data HB: Nov 214

9 AFBMT Data currently reported to the WBMT via the EBMT transplant activity survey 7 reporting teams in South Africa Cape Town (3), Durban, Johannesburg, Pretoria 1 Nigeria Benin City Total transplants in 213: 219 (238 Tx.) Allogeneic: 94 patients (14 Tx.) Autologous: 125 patients (134 Tx.) BM: 12 Tx. (9 allo) PB: 225 Tx. (94 allo) CB: 1 Tx. NGO in official relations with World Health Organization HB: Nov 214

10 AFBMT: Main Indication: allogeneic HSCT IDM, 1% AID,,1% Hemoglobinopathy, 3, 3% IDM, 1, 1% Others, 1, 1% HG, 3% PID, 2% Other NMD,,5% Others, 1% BMF, 17, 18% AML, 28, 3% ST,,4% BMF, 6% AML, 35% HD/NHL, 11% PCD, 3% Other leuk., 1% NHL, 18, 19% ALL, 1, 11% CLL, 3% HD, 1, 1% CLL, 3, 3% MDS/MPS, 9, 1% CML, 3, 3% MDS/MPS, 14% CML, 3% ALL, 17% AFBMT 213 Global 212 NGO in official relations with World Health Organization HB: Nov 214

11 NGO in official relations with World Health Organization HB: Nov 214 AFBMT: Main Indication: donor type PUB CB; 1; 1% PUB CB; 288; 9% Targeted CB; 15; % Other relative ; 3; 3% VUD; 23; 25% HLA identical sibling; 67; 71% VUD; 132; 43% HLA identical sibling; 11389; 38% Twin; 16; % AFBMT 213 Global 212 Other relative ; 2949; 1%

12 NGO in official relations with World Health Organization HB: Nov 214 AFBMT: Donor type by indication: Sibling Haplo Unrelated 2 H S C T AML ALL CML MDS/MPS CLL LPD BMF Other NMD

13 NGO in official relations with World Health Organization HB: Nov 214 AFBMT: Main Indication:allogeneic HSCT Trends over the years by disease and donor type 5 45 Family 5 45 Unrelated Leuk LPD MND Leuk LPD MND

14 NGO in official relations with World Health Organization HB: Nov 214 AFBMT: Main Indication: autologous HSCT Others, 41,,1% NHL, 24, 19% Solid tumors, 1, 1% AID, 1, 1% Leukemias, 1, 8% NMD, 64,,2% ST, 2721, 8% AID, 238, 1% Leukemias, 985, 3% HD, 15, 12% NHL, 1413, 3% PCD, 1793, 49% PCD, 74, 59% HD, 3494, 1% AFBMT 213 Global 212

15 NGO in official relations with World Health Organization HB: Nov 214 AFBMT: Main Indication: autologous HSCT H S C T HD NHL PCD

16 Conclusion and the future Reporting of data is an essential part of the transplant process We need to share our data and experiences in order to move forward Infrastructure exists for transplantation = exists for data reporting Try and encourage non reporting centres/countries to report By providing support Data reporting mechanisms

17 Thank you